XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

XBiotech appoints Jan-Paul Simard as Co-CEO, formalizing a dual leadership structure.

What the company is saying

XBiotech Inc. (NASDAQ:XBIT) has named Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. The announcement highlights the complementary skill sets and scientific backgrounds of both leaders, with Director Tevi Troy emphasizing their shared commitment to advancing True-Human antibody therapies. Dr. Shivaswamy, with 17 years at XBiotech and experience as Senior Scientist, Director, VP of R&D, and Chief Scientific Officer since 2017, is portrayed as providing scientific and operational continuity. She became interim CEO in December 2025 after the retirement of founder John Simard. Jan-Paul Simard joined the company in 2012, moved to clinical development in 2020, and has contributed to clinical trial design in multiple therapeutic areas. The company uses language focused on proactive leadership, operational execution, and delivering value to patients and shareholders, but does not present new operational or financial data. The tone is confident and forward-looking, centering on leadership stability and strategic focus.

What the data suggests

The announcement provides specific personnel facts: Jan-Paul Simard's appointment as Co-CEO is effective immediately, and Dr. Shivaswamy has a 17-year tenure with the company, including key scientific and executive roles. Simard's career progression from R&D assistant in 2012 to clinical development in 2020 is documented, as is his involvement in protocol development for clinical trials in oncology and inflammatory diseases. Dr. Shivaswamy's leadership since December 2025 as interim CEO is confirmed. No financial results, operational metrics, or pipeline milestones are disclosed. The evidence supports a stable succession process and continuity in scientific leadership, but does not provide data to assess business performance, pipeline progress, or financial health. The claims about advancing therapies and manufacturing innovation remain aspirational, with no supporting figures or timelines.

Analysis

This announcement is primarily a leadership update, with the only realised and supported facts being the appointment of Jan-Paul Simard as Co-CEO, Dr. Shivaswamy's tenure and roles, and the timeline of executive transitions. The remainder of the release uses positive, forward-looking language about the company's mission, pipeline, and manufacturing innovation, but provides no operational, clinical, or financial data to substantiate these claims. The tone is optimistic and aspirational, with several statements about redefining standards of care and delivering value, but these are not backed by measurable progress or disclosed milestones. No timelines are given for when the stated benefits might be realised, and there is no mention of capital outlays or immediate earnings impact. The gap between narrative and evidence is moderate: the leadership facts are clear, but the broader company claims are promotional and unsupported by data.

Risk flags

• ●Leadership transitions can disrupt strategic momentum or internal alignment, especially when moving to a co-CEO model. The effectiveness of shared leadership will depend on clear division of responsibilities and decision-making processes.
• ●The announcement provides no detail on how the new co-CEO structure will affect operational execution or the pace of pipeline development. Without operational or financial metrics, investors cannot assess whether the leadership change addresses existing challenges or creates new ones.
• ●Key-person dependency remains a risk, as both co-CEOs are long-tenured insiders with deep institutional knowledge. If either were to depart unexpectedly, the company could face further transition challenges.

Bottom line

XBiotech's appointment of Jan-Paul Simard as Co-CEO alongside Dr. Sushma Shivaswamy formalizes a dual leadership structure, emphasizing continuity and scientific expertise. The announcement is credible on personnel facts, with clear dates and roles, but does not provide operational, clinical, or financial data to gauge business momentum or near-term catalysts. The narrative is aspirational, focusing on the potential of the company's antibody therapies and manufacturing innovation, but lacks measurable progress or defined milestones. Investors should interpret this as a routine governance update rather than a signal of imminent value creation. The most important takeaway is that leadership succession appears stable, but further disclosures are needed to assess the impact on XBiotech's pipeline and financial trajectory.

Announcement summary

(NASDAQ:XBIT) XBiotech Inc. announced that its Board of Directors has elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective October 23, 2026. Director Tevi Troy stated that Dr. Shivaswamy and Jan-Paul Simard bring complementary skill sets, scientific acumen, and a shared commitment to the company's mission, positioning XBiotech to realize the potential of its True-Human antibody therapies. Dr. Sushma Shivaswamy has been with XBiotech for 17 years, previously serving as Senior Scientist, Director, and Vice President of Research & Development, and was appointed Chief Scientific Officer in 2017. As CSO, Dr. Shivaswamy oversaw scientific and technical operations from R&D through GMP production of antibodies. In December 2025, Dr. Shivaswamy was named interim CEO following the retirement of Founder John Simard. Dr. Shivaswamy commented that appointing Jan-Paul Simard as Co-CEO reflects the company's commitment to being proactive, adaptive, and focused on execution, and that his operational continuity will strengthen decision-making. Jan-Paul Simard joined XBiotech in 2012 as an R&D assistant, transitioned to the clinical development team in 2020, and contributed to study design and protocol development for clinical trials in pancreatic cancer, non-small cell lung cancer, osteoarthritis, and rheumatoid arthritis. He has continued his scientific education in Chemistry with Honours at the University of Saskatchewan. Mr. Simard stated that he is honored to step into the leadership role alongside Dr. Shivaswamy and looks forward to advancing new therapies. XBiotech is a fully integrated global biosciences company focused on the discovery, development, and commercialization of therapeutic antibodies based on its True Human discovery platform. The company is advancing antibody therapies for oncology, inflammatory conditions, and infectious diseases. XBiotech is also developing innovative biotech manufacturing technologies to produce new therapies more rapidly, cost-effectively, and flexibly.

Disagree with this article?